MS Medicine Glatiramer Acetate (Copaxone, Glatopa) Poses Risk of Rare but Serious Allergic Reaction, Says FDA
Oliver
January 24, 2025
In a release issued January 22, 2025, the FDA warned multiple sclerosis patients, caregivers, and healthcare professionals of a rare but serious risk associated with the medicine glatiramer acetate, also known on the market as Copaxone and Glatopa. An FDA-approved medicine used in the treatment of “relapsing forms of MS,”
